Latest News
- Bonjesta® Launched Today in Palestine as the Second-Generation Treatment for Morning Sickness
- First Nifedipine Finished-product Preparation in Palestine for the Treatment of Anal Fissures
- ESHRE Virtual 36th Annual Meeting
- Transmed Pharma Acquires Marketing Authorization for Konakion
- First Cardiology Conference, An-Najah National University Hospital
7 November, 2021
Bonjesta® Launched Today in Palestine as the Second-Generation Treatment for Morning Sickness
Ramallah, November 7, 2021 – Transmed Pharma is pleased to announce the launch of Bonjesta® (doxylamine succinate and pyridoxine hydrochloride) replacing its widely popular predecessor, Diclectin. Bonjesta® is indicated for the treatment of nausea and vomiting of pregnancy (NVP), also known as morning sickness, in women who do not respond to conservative management. The combination of ingredients found in Bonjesta® is a proven NVP treatment option with a 60-year safety record of use in market for millions of mothers and their babies, worldwide.
NVP is a medical condition that affects up to 85 percent of pregnant women. NVP can be different for each woman, with symptoms including: nausea, gagging, retching, dry heaving, and vomiting. For most pregnant women, symptoms generally cease at approximately 14 to 16 weeks. However, some women can experience symptoms throughout their pregnancy and might require hospitalization.
Bonjesta® received FDA approval in 2016 based on the safety and efficacy data from Diclectin delayed-release tablets, and three clinical pharmacology studies: a single-dose bioequivalence study, a multiple-dose bioequivalence study and a food-effect study.
Bonjesta® is a multilayer, extended-release formulation that is designed to provide both fast-acting and long-lasting symptom relief. Bonjesta® comes in a pack of 50 tablets, 5 separate blisters, with the advantage of a reduced pill burden (maximum daily dose of two tablets) for better patient adherence. The American College of Obstetrics and Gynecology (ACOG) recommends the combination of ingredients in Bonjesta® as first-line pharmacotherapy for the treatment of NVP after conservative management has failed.
About Duchesnay Duchesnay is a pharmaceutical manufacturing company based in Canada that specializes in the development of pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Duchesnay also commercializes a broad portfolio of products offering safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at various stages of their lives. Please visit the manufacturer’s website at www.duchesnay.com for more information.
Back Next